NCT03035942View on ClinicalTrials.gov

Quality of Recovery After Dexamethasone, Ondansetron or Placebo Intrathecal Morphine Administration

PHASE4CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

January 2, 2017

Primary Completion Date

October 1, 2018

Study Completion Date

November 4, 2019

Conditions
Fractures, BoneNausea and Vomiting, PostoperativePruritusMorphine Adverse ReactionSatisfaction, Personal
Interventions
DRUG

Dexamethasone

Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.

DRUG

Ondansetron

Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.

DRUG

Saline

Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.

Trial Locations (1)

18030-230

Santa Lucinda Hospital, Sorocaba

All Listed Sponsors
lead

Pontificia Universidade Catolica de Sao Paulo

OTHER

NCT03035942 - Quality of Recovery After Dexamethasone, Ondansetron or Placebo Intrathecal Morphine Administration | Biotech Hunter | Biotech Hunter